4D Molecular Therapeutics FDMT
$10.23 −$0.49 (-4.57%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.23 0.00%
Open$10.36
Prev close$10.72
Day range$10.11 – $10.94
Volume691.0K
Market cap$576.76M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$4.15M+4,505.6% YoY
Operating profit-$81.22M-32.7% YoY
Net profit-$78.06M-37.2% YoY
Diluted EPS-$1.08-6.9% YoY
Free cash flow-$56.76M-22.3% YoY
Operating cash flow-$56.71M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-226.0%
Net margin-208.6%
Return on equity-56.7%
Return on assets-47.0%
Return on invested capital-56.8%
Current ratio6.15
Liabilities / assets21.2%
Cash & investments$306.99M
Total debt$33.10M
Net cash (debt)$273.89M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $4.15M | $3.78M | $3.05M | $85.21M | $85.09M |
| Total Operating Revenue | $4.15M | $3.78M | $3.05M | $85.21M | $85.09M |
| Operating Expense | $85.36M | $80.81M | $76.67M | $244.76M | $70.38M |
| Selling and Admin Expenses | $15.59M | $12.52M | $11.69M | $49.06M | $12.77M |
| -General & Admin Expense | $15.59M | $12.52M | $11.69M | $49.06M | $12.77M |
| Research & Development | $69.78M | $68.28M | $64.98M | $195.70M | $57.61M |
| Operating Profit | -$81.22M | -$77.03M | -$73.62M | -$159.55M | $14.72M |
| Net Non-Operating Interest Income (Expense) | $3.94M | $4.26M | $4.86M | $19.48M | $4.70M |
| Non-Operating Interest Income | $3.94M | $4.26M | $4.86M | $19.48M | $4.70M |
| Other Income (Expense) | -$781,000.00 | -$166,000.00 | -$4,000.00 | -$37,000.00 | -$22,000.00 |
| Other Non-Operating Income (Expenses) | -$781,000.00 | -$166,000.00 | -$4,000.00 | -$37,000.00 | -$22,000.00 |
| Pretax Profit | -$78.06M | -$72.94M | -$68.76M | -$140.11M | $19.40M |
| Net Profit | -$78.06M | -$72.94M | -$68.76M | -$140.11M | $19.40M |
| Profit from Continuing Operations | -$78.06M | -$72.94M | -$68.76M | -$140.11M | $19.40M |
| Net Income to Parent Company | -$78.06M | -$72.94M | -$68.76M | -$140.11M | $19.40M |
| Net Income to Common Stockholders | -$78.06M | -$72.94M | -$68.76M | -$140.11M | $19.40M |
| Basic EPS | -$1.08 | -$1.04 | -$1.01 | -$2.42 | $0.43 |
| Diluted EPS | -$1.08 | -$1.04 | -$1.01 | -$2.42 | $0.43 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $428.75M | $492.62M | $512.91M | $566.71M | $566.71M |
| Total Current Assets | $322.29M | $382.96M | $405.36M | $413.13M | $413.13M |
| Cash and Cash Equivalents & Short-Term Investments | $306.99M | $361.33M | $390.89M | $402.66M | $402.66M |
| -Cash and Cash Equivalents | $39.10M | $70.37M | $72.49M | $60.24M | $60.24M |
| -Short Term Investments | $267.89M | $290.96M | $318.40M | $342.41M | $342.41M |
| Receivables | $4.02M | $4.61M | – | – | – |
| -Other Receivables | $4.02M | $4.61M | – | – | – |
| Other Current Assets | $11.28M | $17.01M | $14.47M | $10.48M | $10.48M |
| Total Non-Current Assets | $106.46M | $109.66M | $107.54M | $153.58M | $153.58M |
| Net PPE | $26.98M | $28.93M | $30.94M | $33.01M | $33.01M |
| -Gross PPE | $51.32M | $52.37M | $53.49M | $54.29M | $54.29M |
| -Accumulated Depreciation | -$24.34M | -$23.44M | -$22.55M | -$21.28M | -$21.28M |
| Investments and Advances | $68.04M | $69.30M | $66.74M | $111.38M | $111.38M |
| -Available for Sale Securities | $68.04M | $69.30M | $66.74M | $111.38M | $111.38M |
| Other Non-Current Assets | $11.44M | $11.44M | $9.86M | $9.19M | $9.19M |
| Total Liabilities | $90.81M | $84.96M | $61.07M | $61.05M | $61.05M |
| Total Current Liabilities | $52.39M | $47.67M | $43.40M | $43.99M | $43.99M |
| Payables | $7.88M | $12.52M | $14.69M | $11.16M | $11.16M |
| -Accounts Payable | $7.88M | $12.52M | $14.69M | $11.16M | $11.16M |
| Current Accrued Expenses | $35.21M | $25.43M | $22.87M | $26.87M | $26.87M |
| Short-Term Debt and Capital Lease Obligation | $5.31M | $5.37M | $5.49M | $5.59M | $5.59M |
| -Current Capital Lease Obligation | $5.31M | $5.37M | $5.49M | $5.59M | $5.59M |
| Current Deferred Liabilities | $3.99M | $4.35M | $360,000.00 | $360,000.00 | $360,000.00 |
| Total Non-Current Liabilities | $38.41M | $37.28M | $17.67M | $17.06M | $17.06M |
| Long Term Debt and Capital Lease Obligation | $33.10M | $33.84M | $15.05M | $15.82M | $15.82M |
| -Long Term Debt | $19.68M | $19.59M | – | – | – |
| -Long Term Capital Lease Obligation | $13.42M | $14.26M | $15.05M | $15.82M | $15.82M |
| Derivative Product Liabilities | $397,000.00 | $384,000.00 | $370,000.00 | $358,000.00 | $358,000.00 |
| Non-Current Deferred Liabilities | $2.83M | $2.96M | $2.13M | $745,000.00 | $745,000.00 |
| Other Non-Current Liabilities | $2.08M | $101,000.00 | $121,000.00 | $138,000.00 | $138,000.00 |
| Total Equity | $337.94M | $407.66M | $451.84M | $505.66M | $505.66M |
| Stockholders' Equity | $337.94M | $407.66M | $451.84M | $505.66M | $505.66M |
| Capital Stock | $6,000.00 | $6,000.00 | $5,000.00 | $6,000.00 | $6,000.00 |
| -Common Stock | $6,000.00 | $6,000.00 | $5,000.00 | $6,000.00 | $6,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.27B | $1.27B | $1.24B | $1.22B | $1.22B |
| Retained Earnings | -$936.06M | -$858.00M | -$785.06M | -$716.30M | -$716.30M |
| Gains/Losses Not Affecting Retained Earnings | -$1.01M | -$446,000.00 | -$180,000.00 | $727,000.00 | $727,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$56.71M | -$70.00M | -$68.13M | -$109.08M | $28.55M |
| Net cash flow from continuing operations | -$56.71M | -$70.00M | -$68.13M | -$109.08M | $28.55M |
| Net Income from Continuing Operations | -$78.06M | -$72.94M | -$68.76M | -$140.11M | $19.40M |
| Gain/Loss from Continuing Operations | $21,000.00 | $57,000.00 | $12,000.00 | -$52,000.00 | $13,000.00 |
| Depreciation & Depletion & Amortization | $2.01M | $2.09M | $2.06M | $7.63M | $1.98M |
| Change in Working Capital | $12.09M | -$4.10M | -$4.75M | $6.17M | $2.76M |
| -Change in Prepaid Assets | $6.04M | -$6.53M | -$3.99M | -$424,000.00 | -$3.17M |
| -Change in Payables and Accrued Expense | $8.48M | $2.49M | -$590,000.00 | $14.93M | $6.67M |
| -Change in Other Current Assets | -$1.42M | $18,000.00 | -$670,000.00 | -$4.93M | $192,000.00 |
| -Change in Other Current Liabilities | -$896,000.00 | -$905,000.00 | -$878,000.00 | -$3.19M | -$850,000.00 |
| -Change In Other Working Capital | -$125,000.00 | $830,000.00 | $1.38M | -$209,000.00 | -$90,000.00 |
| Net cash flow from investing | $24.84M | $25.54M | $68.89M | -$92.97M | -$128.85M |
| Net Cash Flow from Continuing Investing Activities | $24.84M | $25.54M | $68.89M | -$92.97M | -$128.85M |
| Net PPE Purchase and Sale | -$49,000.00 | -$66,000.00 | $11,000.00 | -$536,000.00 | $70,000.00 |
| Net Investment Purchase and Sale | $24.89M | $25.61M | $68.88M | -$92.44M | -$128.92M |
| Financing Cash Flow | $604,000.00 | $42.34M | $11.48M | $112.96M | $111.98M |
| Net Cash Flow from Continuing Financing Activities | $604,000.00 | $42.34M | $11.48M | $112.96M | $111.98M |
| Net Issuance Payments Of Debt | $0.00 | – | – | – | – |
| Net Common Stock Issuance | -$38,000.00 | $21.84M | $9.81M | $110.72M | $110.72M |
| Proceeds from Stock Option Exercised | $642,000.00 | $1.24M | $1.67M | $2.24M | $1.26M |
| Ending Cash Balance | $39.10M | $70.37M | $72.49M | $60.24M | $60.24M |
| Net Change in Cash | -$31.27M | -$2.12M | $12.25M | -$89.10M | $11.69M |
| Beginning Cash Balance | $70.37M | $72.49M | $60.24M | $149.34M | $48.56M |
| Free Cash Flow | -$56.76M | -$70.05M | -$68.13M | -$109.62M | $28.62M |
No comments yet — be the first to weigh in on FDMT.
Sign in to join the discussion.